Pnina Fishman

Summary

Country: Israel

Publications

  1. ncbi Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells
    Pnina Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Tel Aviv University, Sackler Faculty of Medicine, Rabin Medical Center, Petach Tikva 49100, Israel
    Oncogene 21:4060-4. 2002
  2. ncbi Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist
    Pnina Fishman
    Can Fite BioPharma Ltd, Kiryat Matalon, Laboratory of Clinical and Tumor Immunology, Felsenstein Medical Research Center, Tel Aviv University Sackler Faculty of Medicine, Rabin Medical Center, Petach Tikva, Israel
    Anticancer Res 23:2077-83. 2003
  3. ncbi Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression
    Avivit Ochaion
    Can-Fite BioPharma Ltd, 10 Bareket Street, Kiryat-Matalon, Petah-Tikva, 49170, Israel
    Arthritis Res Ther 8:R169. 2006
  4. ncbi The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis
    Pnina Fishman
    Can Fite BioPharma Ltd, Kiryat Matalon, Petah Tikva, Israel
    Arthritis Res Ther 8:R33. 2006
  5. ncbi Pharmacology and therapeutic applications of A3 receptor subtype
    Pnina Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Rabin Medical Center, Petach Tikva, Israel
    Curr Top Med Chem 3:463-9. 2003
  6. ncbi An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B
    Pnina Fishman
    Can Fite BioPharma Ltd, Kiryat Matalon, Petach Tikva 49170, Israel
    Oncogene 23:2465-71. 2004
  7. ncbi The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition
    Lea Madi
    Can Fite BioPharma Ltd, Kiryat Matalon, Petach Tikva, Israel
    Clin Cancer Res 10:4472-9. 2004
  8. ncbi A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition
    Lea Madi
    Can Fite BioPharma Ltd, Kiryat Matalon, Petach Tikva 49170, Israel
    J Biol Chem 278:42121-30. 2003
  9. ncbi Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models
    Ehud Baharav
    Can-Fite BioPharma Ltd, 10 Bareket Street, Kiryat-Matalon, Petach-Tikva, Tel Aviv, Israel 49170
    J Rheumatol 32:469-76. 2005
  10. ncbi Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level
    Lea Madi
    Can Fite BioPharma Ltd, Kiryat Matalon, Petah Tikva, Israel
    J Rheumatol 34:20-6. 2007

Collaborators

  • Yair Molad
  • Reuven Mader
  • Howard Amital
  • Moshe Mittelman
  • V Strand
  • Sara Bar-Yehuda
  • Lea Madi
  • Avivit Ochaion
  • Shira Cohen
  • Faina Barer
  • Michael H Silverman
  • Sara Bar Yehuda
  • Arie Harish
  • William D Kerns
  • Moshe Tishler
  • Tatiana Reitblat
  • Motti Farbstein
  • Pnina Langevitz
  • Sari Fishman-Furman
  • Ehud Baharav
  • Daniel Silberman
  • Lea Rath-Wolfson
  • Shira Cohn
  • Eti Ardon
  • Dror Luger
  • Jose Maria Garcia Ruiz de Morales
  • Rachel R Caspi
  • Galina Zozulya
  • Renana Patokaa
  • Phyllis B Silver
  • Muhamad Adawi
  • Michael Rozenbaum
  • Itzhak Rosner
  • Menachem Nahir
  • Amir Tanay
  • Doron Markovits
  • Lesly Green
  • Joshua Friedman
  • Alan Rubinow
  • Ilan Cohn
  • Dan Caspi
  • Avivit Ochayin
  • Luis Del Valle
  • Georginia Perez-Liz
  • Yair Levi
  • Alexander Reitblat
  • Alexander Zabutti
  • Slosman Gery
  • Marisa Halpren
  • Abraham Weinberger
  • Maya Shkapenuk
  • Gil Ohana
  • Abigail Erlanger
  • Ofer Merimski
  • Oshra Arnon
  • Gil Hohana
  • Dana Barak

Detail Information

Publications19

  1. ncbi Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells
    Pnina Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Tel Aviv University, Sackler Faculty of Medicine, Rabin Medical Center, Petach Tikva 49100, Israel
    Oncogene 21:4060-4. 2002
    ..These observations which link cAMP to the Wnt signaling pathway provide mechanistic evidence for the involvement of Wnt pathway via its key elements GSK-3beta and beta-catenin in the anti-tumor activity of A3AR agonists...
  2. ncbi Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist
    Pnina Fishman
    Can Fite BioPharma Ltd, Kiryat Matalon, Laboratory of Clinical and Tumor Immunology, Felsenstein Medical Research Center, Tel Aviv University Sackler Faculty of Medicine, Rabin Medical Center, Petach Tikva, Israel
    Anticancer Res 23:2077-83. 2003
    ....
  3. ncbi Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression
    Avivit Ochaion
    Can-Fite BioPharma Ltd, 10 Bareket Street, Kiryat-Matalon, Petah-Tikva, 49170, Israel
    Arthritis Res Ther 8:R169. 2006
    ..In conclusion, the data presented here indicate that MTX induces increased A3AR expression and exhibition, thereby potentiating the inhibitory effect of CF101 and supporting combined use of these drugs to treat RA...
  4. ncbi The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis
    Pnina Fishman
    Can Fite BioPharma Ltd, Kiryat Matalon, Petah Tikva, Israel
    Arthritis Res Ther 8:R33. 2006
    ..The finding that the A3AR expression level in the peripheral blood mononuclear cells and in the DLN reflects the receptor status in the remote inflammatory site suggests use of the A3AR as a follow-up biomarker...
  5. ncbi Pharmacology and therapeutic applications of A3 receptor subtype
    Pnina Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Rabin Medical Center, Petach Tikva, Israel
    Curr Top Med Chem 3:463-9. 2003
    ..Antagonists to A(3)AR may be implemented to the therapy of asthma and additional allergic conditions...
  6. ncbi An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B
    Pnina Fishman
    Can Fite BioPharma Ltd, Kiryat Matalon, Petach Tikva 49170, Israel
    Oncogene 23:2465-71. 2004
    ..This is the first demonstration that A(3)AR activation induces colon carcinoma growth inhibition via the modulation of the key proteins GSK-3 beta and NF-kappa B...
  7. ncbi The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition
    Lea Madi
    Can Fite BioPharma Ltd, Kiryat Matalon, Petach Tikva, Israel
    Clin Cancer Res 10:4472-9. 2004
    ..To additionally elucidate whether A(3)AR is a specific target, a survey of its expression in tumor versus adjacent normal cells was conducted...
  8. ncbi A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition
    Lea Madi
    Can Fite BioPharma Ltd, Kiryat Matalon, Petach Tikva 49170, Israel
    J Biol Chem 278:42121-30. 2003
    ..Altogether, our observations tie the fate of A3AR to modulation of downstream molecular mechanisms leading to tumor growth inhibition both in vitro and in vivo...
  9. ncbi Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models
    Ehud Baharav
    Can-Fite BioPharma Ltd, 10 Bareket Street, Kiryat-Matalon, Petach-Tikva, Tel Aviv, Israel 49170
    J Rheumatol 32:469-76. 2005
    ..The beneficial activity of the drugs at the low dose demonstrates that the effect is A3AR mediated...
  10. ncbi Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level
    Lea Madi
    Can Fite BioPharma Ltd, Kiryat Matalon, Petah Tikva, Israel
    J Rheumatol 34:20-6. 2007
    ..We examined the role of nuclear factor-kappaB (NF-kappaB), a transcription factor present in the A3AR promoter, in mediating receptor upregulation...
  11. ncbi Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents
    Sara Bar-Yehuda
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel-Aviv University, Rabin Medical Center, Petach-Tikva, 49100 Israel
    Exp Hematol 30:1390-8. 2002
    ..CONCLUSION: CF101 induced upregulation of the PI3K/NF-kappaB pathway leading to G-CSF production, resulting in myeloprotective effect in cyclophosphamide-treated mice...
  12. ncbi A3 adenosine receptor agonist potentiates natural killer cell activity
    Arie Harish
    Department of Surgery A/B and Pathology, Rabin Medical Center, Campus Golda, Sackler Faculty of Medicine, Tel-Aviv University, Petach-Tikva 49100, Israel
    Int J Oncol 23:1245-9. 2003
    ..Taken together, the ability of Cl-IB-MECA to inhibit tumor development via the activation of NK cells is an additional mechanism which accounts for the anti-tumor effect of A3AR agonists...
  13. ncbi CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model
    Sara Bar-Yehuda
    Can-Fite BioPharma Ltd, Kiryat-Matalon, Petach-Tikva 49170, Israel
    Neoplasia 7:85-90. 2005
    ..These results show that CF101 potentiates the cytotoxic effect of 5-FU, thus preventing drug resistance. The myeloprotective effect of CF101 suggests its development as an add-on treatment to 5-FU...
  14. ncbi The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis
    Sara Bar Yehuda
    Can Fite BioPharma, 10 Bareket Street, PO Box 7537, Petach Tikva 49170, Israel
    Expert Opin Investig Drugs 16:1601-13. 2007
    ..Taken together, this information suggests that A(3)AR agonists may be a new family of orally bioavailable drugs to be developed as potent inhibitors of autoimmune-inflammatory diseases...
  15. ncbi A3 adenosine receptor as a target for cancer therapy
    Pnina Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Tel Aviv University, Rabin Medical Center, Petach Tikva 49100, Israel
    Anticancer Drugs 13:437-43. 2002
    ..The A3AR agonists are thus a promising new class of agents for cancer therapy...
  16. ncbi Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial
    Michael H Silverman
    Can Fite BioPharma Ltd, Petach Tikva, Israel
    J Rheumatol 35:41-8. 2008
    ..CF101 is a highly specific orally bioavailable A3AR agonist...
  17. ncbi IVIg to prevent tumor metastases (Review)
    Pnina Fishman
    Felsenstein Medical Research Center, Rabin Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Petach-Tikva 49100, Israel
    Int J Oncol 21:875-80. 2002
    ..The lack of serious side effects with the remarkable decrease in metastatic spread make IVIg a suitable adjuvant therapy in early and advanced cancer conditions...
  18. ncbi Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101
    Sara Bar-Yehuda
    Can Fite BioPharma, Petach Tikva, Israel
    Int J Mol Med 28:727-31. 2011
    ..Overall, the present study data point towards a marked anti-inflammatory effect of CF101 in EAU and support further exploration of this small molecule drug for the treatment of uveitis...
  19. ncbi Pharmacological and therapeutic effects of A(3) adenosine receptor agonists
    Pnina Fishman
    Can Fite BioPharma Ltd, Kiryat Matalon, 10 Bareket St, P O Box 7537, Petah Tikva 49170, Israel
    Drug Discov Today 17:359-66. 2012
    ....